{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:59:51Z","timestamp":1772747991148,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T00:00:00Z","timestamp":1725667200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010721","name":"Ironwood Pharmaceuticals, Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40261-024-01387-7","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T11:01:56Z","timestamp":1725706916000},"page":"703-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Cost Effectiveness of Adjunctive Treatments for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease"],"prefix":"10.1007","volume":"44","author":[{"given":"Ulysses S.","family":"Rosas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-9479","authenticated-orcid":false,"given":"Christopher V.","family":"Almario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brennan M. R.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,7]]},"reference":[{"key":"1387_CR1","doi-asserted-by":"crossref","unstructured":"Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900\u20131920 (quiz 1943).","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"issue":"5","key":"1387_CR2","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1053\/j.gastro.2019.12.014","volume":"158","author":"SD Delshad","year":"2020","unstructured":"Delshad SD, Almario CV, Chey WD, Spiegel BMR. Prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory symptoms. Gastroenterology. 2020;158(5):1250-1261.e1252.","journal-title":"Gastroenterology"},{"issue":"6","key":"1387_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871\u201380.","journal-title":"Gut"},{"issue":"2","key":"1387_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/MCG.0b013e31815ea27b","volume":"43","author":"GD Eslick","year":"2009","unstructured":"Eslick GD, Talley NJ. Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study. J Clin Gastroenterol. 2009;43(2):111\u20137.","journal-title":"J Clin Gastroenterol"},{"issue":"3 Suppl","key":"1387_CR5","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S0002-9270(03)00010-8","volume":"98","author":"JJ Ofman","year":"2003","unstructured":"Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98(3 Suppl):S8-s14.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1387_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","volume":"156","author":"AF Peery","year":"2019","unstructured":"Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156(1):254-272.e211.","journal-title":"Gastroenterology"},{"issue":"3","key":"1387_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S0002-9343(97)00354-9","volume":"104","author":"DA Revicki","year":"1998","unstructured":"Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med. 1998;104(3):252\u20138.","journal-title":"Am J Med"},{"issue":"2","key":"1387_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1053\/j.gastro.2008.12.015","volume":"136","author":"JE Everhart","year":"2009","unstructured":"Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136(2):376\u201386.","journal-title":"Gastroenterology"},{"issue":"6","key":"1387_CR9","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1365-2036.2010.04406.x","volume":"32","author":"H El-Serag","year":"2010","unstructured":"El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32(6):720\u201337.","journal-title":"Aliment Pharmacol Ther"},{"key":"1387_CR10","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.2147\/DDDT.S306371","volume":"15","author":"V Savarino","year":"2021","unstructured":"Savarino V, Marabotto E, Zentilin P, Demarzo MG, de Bortoli N, Savarino E. Pharmacological management of gastro-esophageal reflux disease: an update of the state-of-the-art. Drug Des Dev Ther. 2021;15:1609\u201321.","journal-title":"Drug Des Dev Ther"},{"issue":"9","key":"1387_CR11","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.14309\/ajg.0000000000000734","volume":"115","author":"CP Gyawali","year":"2020","unstructured":"Gyawali CP, Carlson DA, Chen JW, Patel A, Wong RJ, Yadlapati RH. ACG Clinical Guidelines: clinical use of esophageal physiologic testing. Am J Gastroenterol. 2020;115(9):1412\u201328.","journal-title":"Am J Gastroenterol"},{"key":"1387_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/CEG.S121056","volume":"11","author":"J Mermelstein","year":"2018","unstructured":"Mermelstein J, Chait Mermelstein A, Chait MM. Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions. Clin Exp Gastroenterol. 2018;11:119\u201334.","journal-title":"Clin Exp Gastroenterol"},{"issue":"8","key":"1387_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1053\/j.gastro.2020.02.031","volume":"158","author":"MF Vaezi","year":"2020","unstructured":"Vaezi MF, Fass R, Vakil N, et al. IW-3718 reduces heartburn severity in patients with refractory gastroesophageal reflux disease in a randomized trial. Gastroenterology. 2020;158(8):2093\u2013103.","journal-title":"Gastroenterology"},{"issue":"1","key":"1387_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14309\/ajg.0000000000001538","volume":"117","author":"PO Katz","year":"2022","unstructured":"Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27\u201356.","journal-title":"Am J Gastroenterol"},{"issue":"16","key":"1387_CR15","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1811424","volume":"381","author":"SJ Spechler","year":"2019","unstructured":"Spechler SJ, Hunter JG, Jones KM, et al. Randomized trial of medical versus surgical treatment for refractory heartburn. N Engl J Med. 2019;381(16):1513\u201323.","journal-title":"N Engl J Med"},{"key":"1387_CR16","unstructured":"Bureau of Labor Statistics. CPI Inflation Calculator. 2024; http:\/\/www.bls.gov\/data\/inflation_calculator.htm. Accessed 23 July 2024."},{"key":"1387_CR17","unstructured":"Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry. 2020. http:\/\/www.cearegistry.org. Accessed 2 Jan 2024."},{"issue":"2","key":"1387_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1572-0241.2005.41210.x","volume":"100","author":"S Charbel","year":"2005","unstructured":"Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005;100(2):283\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"1387_CR19","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/j.1572-0241.2008.02033.x","volume":"103","author":"GJ Hemmink","year":"2008","unstructured":"Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: \u201con\u201d or \u201coff\u201d proton pump inhibitor? Am J Gastroenterol. 2008;103(10):2446\u201353.","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"1387_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137.","journal-title":"N Engl J Med"},{"issue":"6","key":"1387_CR21","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11(6):e833\u201342.","journal-title":"Lancet Glob Health"},{"key":"1387_CR22","volume-title":"Cost-effectiveness analysis in health: a practical approach","author":"P Muennig","year":"2016","unstructured":"Muennig P, Bounthavong M. Cost-effectiveness analysis in health: a practical approach. New York: Wiley; 2016."},{"issue":"8","key":"1387_CR23","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1007\/s00464-015-4629-4","volume":"30","author":"C Afaneh","year":"2016","unstructured":"Afaneh C, Zoghbi V, Finnerty BM, et al. BRAVO esophageal pH monitoring: more cost-effective than empiric medical therapy for suspected gastroesophageal reflux. Surg Endosc. 2016;30(8):3454\u201360.","journal-title":"Surg Endosc"},{"key":"1387_CR24","doi-asserted-by":"crossref","unstructured":"Kleiman DA, Beninato T, Bosworth BP, et al. Early referral for esophageal pH monitoring is more cost-effective than prolonged empiric trials of proton-pump inhibitors for suspected gastroesophageal reflux disease. J Gastrointest Surg. 2014;18(1):26\u201333 (discussion 33\u201324).","DOI":"10.1007\/s11605-013-2327-x"},{"issue":"11","key":"1387_CR25","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1111\/j.1365-2036.2012.05086.x","volume":"35","author":"J Tack","year":"2012","unstructured":"Tack J, Becher A, Mulligan C, Johnson DA. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther. 2012;35(11):1257\u201366.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1387_CR26","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/11531670-000000000-00000","volume":"30","author":"S Toghanian","year":"2010","unstructured":"Toghanian S, Wahlqvist P, Johnson DA, Bolge SC, Liljas B. The burden of disrupting gastro-oesophageal reflux disease: a database study in USA and European cohorts. Clin Drug Investig. 2010;30(3):167\u201378.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1387_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.gie.2009.08.024","volume":"71","author":"CH Poh","year":"2010","unstructured":"Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc. 2010;71(1):28\u201334.","journal-title":"Gastrointest Endosc"},{"issue":"8","key":"1387_CR28","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1007\/s00464-015-4659-y","volume":"30","author":"HF Warren","year":"2016","unstructured":"Warren HF, Reynolds JL, Lipham JC, et al. Multi-institutional outcomes using magnetic sphincter augmentation versus Nissen fundoplication for chronic gastroesophageal reflux disease. Surg Endosc. 2016;30(8):3289\u201396.","journal-title":"Surg Endosc"},{"key":"1387_CR29","unstructured":"Malik TF, Gnanapandithan K, Singh K. Peptic ulcer disease. 2023. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing."},{"issue":"2","key":"1387_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","volume":"154","author":"ES Dellon","year":"2018","unstructured":"Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154(2):319-332.e313.","journal-title":"Gastroenterology"},{"issue":"9","key":"1387_CR31","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1111\/j.1365-2982.2010.01511.x","volume":"22","author":"DC Sadowski","year":"2010","unstructured":"Sadowski DC, Ackah F, Jiang B, Svenson LW. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil. 2010;22(9):e256-261.","journal-title":"Neurogastroenterol Motil"},{"issue":"5","key":"1387_CR32","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00464-019-07021-4","volume":"34","author":"S Ayazi","year":"2020","unstructured":"Ayazi S, Zaidi AH, Zheng P, et al. Comparison of surgical payer costs and implication on the healthcare expenses between laparoscopic magnetic sphincter augmentation (MSA) and laparoscopic Nissen fundoplication (LNF) in a large healthcare system. Surg Endosc. 2020;34(5):2279\u201386.","journal-title":"Surg Endosc"},{"issue":"2","key":"1387_CR33","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/SLA.0000000000002789","volume":"270","author":"BE Louie","year":"2019","unstructured":"Louie BE, Smith CD, Smith CC, et al. Objective evidence of reflux control after magnetic sphincter augmentation: one year results from a post approval study. Ann Surg. 2019;270(2):302\u20138.","journal-title":"Ann Surg"},{"key":"1387_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijsu.2018.02.041","volume":"52","author":"A Aiolfi","year":"2018","unstructured":"Aiolfi A, Asti E, Bernardi D, et al. Early results of magnetic sphincter augmentation versus fundoplication for gastroesophageal reflux disease: systematic review and meta-analysis. Int J Surg. 2018;52:82\u20138.","journal-title":"Int J Surg"},{"issue":"5","key":"1387_CR35","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1097\/SLA.0000000000001785","volume":"265","author":"E Asti","year":"2017","unstructured":"Asti E, Siboni S, Lazzari V, Bonitta G, Sironi A, Bonavina L. Removal of the magnetic sphincter augmentation device: surgical technique and results of a single-center cohort study. Ann Surg. 2017;265(5):941\u20135.","journal-title":"Ann Surg"},{"issue":"5","key":"1387_CR36","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.cgh.2015.05.028","volume":"14","author":"RA Ganz","year":"2016","unstructured":"Ganz RA, Edmundowicz SA, Taiganides PA, et al. Long-term outcomes of patients receiving a magnetic sphincter augmentation device for gastroesophageal reflux. Clin Gastroenterol Hepatol. 2016;14(5):671\u20137.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"1387_CR37","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1089\/lap.2015.0394","volume":"25","author":"G Saino","year":"2015","unstructured":"Saino G, Bonavina L, Lipham JC, Dunn D, Ganz RA. Magnetic sphincter augmentation for gastroesophageal reflux at 5 years: final results of a pilot study show long-term acid reduction and symptom improvement. J Laparoendosc Adv Surg Tech A. 2015;25(10):787\u201392.","journal-title":"J Laparoendosc Adv Surg Tech A"},{"issue":"8","key":"1387_CR38","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s00464-018-6544-y","volume":"33","author":"JM Tatum","year":"2019","unstructured":"Tatum JM, Alicuben E, Bildzukewicz N, Samakar K, Houghton CC, Lipham JC. Removing the magnetic sphincter augmentation device: operative management and outcomes. Surg Endosc. 2019;33(8):2663\u20139.","journal-title":"Surg Endosc"},{"issue":"3","key":"1387_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/01.sla.0000114225.46280.fe","volume":"239","author":"M Catarci","year":"2004","unstructured":"Catarci M, Gentileschi P, Papi C, et al. Evidence-based appraisal of antireflux fundoplication. Ann Surg. 2004;239(3):325\u201337.","journal-title":"Ann Surg"},{"issue":"1","key":"1387_CR40","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.surg.2014.05.027","volume":"157","author":"LM Funk","year":"2015","unstructured":"Funk LM, Zhang JY, Drosdeck JM, Melvin WS, Walker JP, Perry KA. Long-term cost-effectiveness of medical, endoscopic and surgical management of gastroesophageal reflux disease. Surgery. 2015;157(1):126\u201336.","journal-title":"Surgery"},{"key":"1387_CR41","unstructured":"Centers for Medicare & Medicaid Services. National Average Drug Acquisition Cost. 2024. https:\/\/data.medicaid.gov\/dataset\/99315a95-37ac-4eee-946a-3c523b4c481e. Accessed 23 July 2024."},{"key":"1387_CR42","unstructured":"Centers for Medicare & Medicaid Services. Physician Fee Schedule. 2024. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search?Y=0&T=4&HT=0&CT=3&H1=43284&M=5. Accessed 23 July 2024."},{"key":"1387_CR43","unstructured":"Centers for Medicare & Medicaid Services. Anesthesiologists Center. 2024. https:\/\/www.cms.gov\/Center\/Provider-Type\/Anesthesiologists-Center. Accessed 23 July 2024."},{"key":"1387_CR44","unstructured":"Centers for Medicare & Medicaid Services. Ambulatory Surgical Center (ASC) Payment. 2024. https:\/\/www.cms.gov\/medicare\/payment\/prospective-payment-systems\/ambulatory-surgical-center-asc\/asc-payment-rates-addenda. Accessed 23 July 2024."},{"key":"1387_CR45","unstructured":"Agency for Healthcare and Research Quality. HCUPnet. 2017; https:\/\/hcupnet.ahrq.gov\/#setup. Accessed 28 Apr 2020."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01387-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01387-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01387-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,6]],"date-time":"2024-10-06T00:06:24Z","timestamp":1728173184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01387-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01387-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"4 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by SCELC, Statewide California Electronic Library Consortium. This investigator-initiated study was funded by Ironwood Pharmaceuticals. No branded products or services are discussed in this manuscript. The analyses and manuscript were conducted and prepared solely by the investigators. The Cedars-Sinai Center for Outcomes Research and Education (CS-CORE) is supported by The Marc and Sheri Rapaport Fund for Digital Health Sciences & Precision Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ulysses S. Rosas: No relevant disclosures; Christopher V. Almario, MD, MSHPM: Consulted for Exact Sciences, Greenspace Labs, Owlstone Medical, and Salix Pharmaceuticals; grants to his institution from Freenome; stock options in My Total Health; Kyung-Sang Yu, MD, PhD, MBA: No relevant disclosures; Brennan M.R. Spiegel, MD, MSHS: Consulted for Ardelyx, Exact Sciences, Ferring; leadership roles in the American College of Gastroenterology (Governor for Southern California); research grants to his institution from Abbvie, Amgen, Ironwood, Salix\/Bausch, Takeda; patents for My Nutrition Health, digital manometry, AbStats sensor; co-founder of VRx Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable; this economic analysis was exempt from review by the Cedars-Sinai Institutional Review Board as it used de-identified, publicly available data without involving direct interaction with human subjects or identifiable private information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and analyzed in the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"<i>Christopher V. Almario, MD, MSHPM; Brennan M.R. Spiegel, MD, MSHS<\/i>: substantial contributions to the conception and design of the work; acquisition, analysis, and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published. <i>Ulysses S. Rosas, MD; Kyung-Sang Yu, MD, PhD, MBA<\/i>: substantial contributions to the design of the work; acquisition, analysis, and interpretation of data for the work; drafting the work and revising it critically for important intellectual content; final approval of the version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}